Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 2/20 | 0.33 |
| ▸ | MAX | P61244 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120209 | 1.00 | AGTR1 (0.38) | AGTR1ALOX5S1PR1S1PR3MYC | |
| SCHEMBL4139334 | 0.83 | ALOX5 (0.39) | AGTR1ALOX5S1PR1S1PR3MYC | |
| SCHEMBL4139330 | 0.83 | ALOX5 (0.39) | AGTR1ALOX5S1PR1S1PR3MYC | |
| SCHEMBL4131454 | 0.79 | ALOX5 (0.45) | ALOX5MYCMAXMAPTMEN1 | |
| SCHEMBL4131451 | 0.79 | ALOX5 (0.45) | ALOX5MYCMAXMAPTMEN1 | |
| SCHEMBL4127992 | 0.78 | ALOX5 (0.45) | ALOX5MYCMAXMAPTPOLB | |
| SCHEMBL4127994 | 0.78 | ALOX5 (0.45) | ALOX5MYCMAXMAPTPOLB | |
| SCHEMBL4122948 | 0.73 | ALOX5 (0.48) | ALOX5 | |
| SCHEMBL4122944 | 0.73 | ALOX5 (0.48) | ALOX5 | |
| Acetic Acid SCHEMBL4128303 | 0.71 | FFAR1 (0.40) | S1PR1S1PR3FFAR1AKR1B1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | AGTR1 588/4885ALOX5 3505/4885S1PR1 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.